User login
Key clinical point: Three months of induction therapy with modified folinic acid-fluorouracil-oxaliplatin 6 (mFOLFOX6)/capecitabine-oxaliplatin (CAPOX) downstaged early-stage I/IIA rectal cancer in the majority of selected patients, allowing a well-tolerated organ-preserving surgery.
Major finding: Induction therapy with mFOLFOX6/CAPOX followed by transanal excision surgery (TES) downstaged tumors to ypT0/T1 cN0 in 57% of patients, with 79% (90% CI 69%-88%) of overall patients achieving organ preservation with no unexpected toxicities.
Study details: Findings are from the phase 2 NEO trial including 58 patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma with no unfavorable histologic characteristics who were treated with 3 months of chemotherapy (mFOLFOX6/CAPOX), of which 56 proceeded to TES.
Disclosures: This study was supported by the Canadian Cancer Society. Some authors declared receiving honoraria or research funding from or serving as consultants or advisors or on speakers’ bureau for various sources.
Source: Kennecke HF et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2022 (Aug 18). Doi: 10.1200/JCO.22.00184
Key clinical point: Three months of induction therapy with modified folinic acid-fluorouracil-oxaliplatin 6 (mFOLFOX6)/capecitabine-oxaliplatin (CAPOX) downstaged early-stage I/IIA rectal cancer in the majority of selected patients, allowing a well-tolerated organ-preserving surgery.
Major finding: Induction therapy with mFOLFOX6/CAPOX followed by transanal excision surgery (TES) downstaged tumors to ypT0/T1 cN0 in 57% of patients, with 79% (90% CI 69%-88%) of overall patients achieving organ preservation with no unexpected toxicities.
Study details: Findings are from the phase 2 NEO trial including 58 patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma with no unfavorable histologic characteristics who were treated with 3 months of chemotherapy (mFOLFOX6/CAPOX), of which 56 proceeded to TES.
Disclosures: This study was supported by the Canadian Cancer Society. Some authors declared receiving honoraria or research funding from or serving as consultants or advisors or on speakers’ bureau for various sources.
Source: Kennecke HF et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2022 (Aug 18). Doi: 10.1200/JCO.22.00184
Key clinical point: Three months of induction therapy with modified folinic acid-fluorouracil-oxaliplatin 6 (mFOLFOX6)/capecitabine-oxaliplatin (CAPOX) downstaged early-stage I/IIA rectal cancer in the majority of selected patients, allowing a well-tolerated organ-preserving surgery.
Major finding: Induction therapy with mFOLFOX6/CAPOX followed by transanal excision surgery (TES) downstaged tumors to ypT0/T1 cN0 in 57% of patients, with 79% (90% CI 69%-88%) of overall patients achieving organ preservation with no unexpected toxicities.
Study details: Findings are from the phase 2 NEO trial including 58 patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma with no unfavorable histologic characteristics who were treated with 3 months of chemotherapy (mFOLFOX6/CAPOX), of which 56 proceeded to TES.
Disclosures: This study was supported by the Canadian Cancer Society. Some authors declared receiving honoraria or research funding from or serving as consultants or advisors or on speakers’ bureau for various sources.
Source: Kennecke HF et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2022 (Aug 18). Doi: 10.1200/JCO.22.00184